OTCMKTS:ORTIF - Ortho Regenerative Technologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.35
  • Forecasted Upside: 579.07 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.20
+0 (0.00%)

This chart shows the closing price for ORTIF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ortho Regenerative Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORTIF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORTIF

Analyst Price Target is $1.35
▲ +579.07% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Ortho Regenerative Technologies in the last 3 months. The average price target is $1.35, with a high forecast of $1.35 and a low forecast of $1.35. The average price target represents a 579.07% upside from the last price of $0.20.

This chart shows the closing price for ORTIF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Ortho Regenerative Technologies.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/11/2022Noble FinancialInitiated CoverageOutperformC$1.35
(Data available from 8/10/2017 forward)

News Sentiment Rating

0.27 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/12/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.
Ortho Regenerative Technologies logo
Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing, as well as ORTHO-T, a biopolymer formulation for tendon healing and regeneration. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.
Read More

Today's Range

Now: $0.20
Low: $0.20
High: $0.20

50 Day Range

MA: $0.19
Low: $0.15
High: $0.21

52 Week Range

Now: $0.20
Low: $0.13
High: $0.45

Volume

N/A

Average Volume

11 shs

Market Capitalization

$6.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Ortho Regenerative Technologies?

The following Wall Street research analysts have issued stock ratings on Ortho Regenerative Technologies in the last year: Noble Financial.
View the latest analyst ratings for ORTIF.

What is the current price target for Ortho Regenerative Technologies?

1 Wall Street analysts have set twelve-month price targets for Ortho Regenerative Technologies in the last year. Their average twelve-month price target is $1.35, suggesting a possible upside of 579.1%. Noble Financial has the highest price target set, predicting ORTIF will reach $1.35 in the next twelve months. Noble Financial has the lowest price target set, forecasting a price of $1.35 for Ortho Regenerative Technologies in the next year.
View the latest price targets for ORTIF.

What is the current consensus analyst rating for Ortho Regenerative Technologies?

Ortho Regenerative Technologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ORTIF will outperform the market and that investors should add to their positions of Ortho Regenerative Technologies.
View the latest ratings for ORTIF.

What other companies compete with Ortho Regenerative Technologies?

How do I contact Ortho Regenerative Technologies' investor relations team?

The company's listed phone number is (514) 782-0951 and its investor relations email address is [email protected] The official website for Ortho Regenerative Technologies is www.orthorti.com. Learn More about contacing Ortho Regenerative Technologies investor relations.